Read the full stored bill text
HB 1734-FN - AS AMENDED BY THE SENATE
11Mar2026... 0666h
05/14/2026 1864s
2026 SESSION
26-2801
05/06
HOUSE BILL
1734-FN
AN ACT
establishing a committee to study the feasibility of establishing experimental treatment centers in New Hampshire and the oversight thereof.
SPONSORS: Rep. Kesselring, Hills. 18; Rep. Cole, Hills. 26; Rep. Mazur, Hills. 44; Rep. Polozov, Merr. 10; Rep. D. McGuire, Merr. 14; Rep. Markell, Rock. 18; Rep. Bernardy, Rock. 36; Rep. Kofalt, Hills. 32; Rep. Osborne, Rock. 2; Rep. Miles, Hills. 12; Sen. Murphy, Dist 16; Sen. Sullivan, Dist 18; Sen. Innis, Dist 7; Sen. McGough, Dist 11
COMMITTEE: Health, Human Services and Elderly Affairs
─────────────────────────────────────────────────────────────────
AMENDED ANALYSIS
This bill establishes a committee to study the feasibility of establishing experimental treatment centers in New Hampshire and the oversight thereof.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Explanation: Matter added to current law appears in
bold italics.
Matter removed from current law appears [
in brackets and struckthrough.
]
Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.
11Mar2026... 0666h
05/14/2026 1864s 26-2801
05/06
STATE OF NEW HAMPSHIRE
In the Year of Our Lord Two Thousand Twenty-Six
AN ACT
establishing a committee to study the feasibility of establishing experimental treatment centers in New Hampshire and the oversight thereof.
Be it Enacted by the Senate and House of Representatives in General Court convened:
1 Committee Established. There is established a committee to study the feasibility of establishing experimental treatment centers in New Hampshire and the oversight thereof.
2 Membership and Compensation.
I. The members of the committee shall be as follows:
(a) Two members of the senate, appointed by the president of the senate, one of whom shall be a member of the minority party.
(b) Three members of the house of representatives, appointed by the speaker of the house of representatives, one of whom shall be a member of the minority party.
II. Members of the committee shall receive mileage at the legislative rate when attending to the duties of the committee.
3 Duties. The committee shall:
I. Determine what would be needed for sufficient oversight of experimental treatment centers by the department of health and human services, the bureau of consumer protection at the department of justice, and the office of professional licensure and certification.
II. Solicit information and testimony from the department of health and human services, the bureau of consumer protection, and the office of profession licensure and certification on what they would require in terms of legislation, rules, appropriation, and any potential federal waivers to properly oversee these centers.
III. Solicit information and testimony from the current operator of an experimental treatment center or a trade group representing experimental treatment centers.
IV. Solicit information and testimony from a governmental oversight body from another state that currently allows experimental treatment centers.
V. Solicit information and testimony from an individual or entity with expertise in the FDA drug and device approval process.
VI. Solicit information and testimony from an individual or entity with expertise in current Good Manufacturing Practice (cGMP) for drug manufacturing.
VII. Research experimental treatment centers in other states, including all benefits and consequences of those centers in those states, including patient outcomes and costs to the state's health care system.
VIII. Research the feasibility of proper oversight of these facilities, including oversight challenges in other states that have implemented these experimental treatment centers.
4 Chairperson; Quorum. The members of the study committee shall elect a chairperson from among the members. The first meeting of the committee shall be called by the first-named senate member. The first meeting of the committee shall be held within 45 days of the effective date of this section. Four members of the committee shall constitute a quorum.
5 Report. The committee shall report its findings and any recommendations for proposed legislation to the president of the senate, the speaker of the house of representatives, the senate clerk, the house clerk, the governor, and the state library on or before November 1, 2026.
6 Effective Date. This act shall take effect upon its passage.
LBA
26-2801
05/21/2026
HB 1734-FN-
FISCAL NOTE
AS AMENDED BY THE SENATE (AMENDMENT #2026-1864s)
AN ACT
establishing a committee to study the feasibility of establishing experimental treatment centers in New Hampshire and the oversight thereof.
FISCAL IMPACT:
The Office of Legislative Budget Assistant states this bill has no fiscal impact on state, county
and local expenditures or revenue.
AGENCIES CONTACTED:
None